Display Settings:

Format

Send to:

Choose Destination
J Rheumatol. 2006 May;33(5):862-4.

Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis.

Author information

  • 1Universidad Peruana Cayetano Heredia, Lima, Peru.

Abstract

OBJECTIVE:

To investigate the clinical efficacy, safety, tolerability, and toxicity profile of a metabolically stable antifolate, CH-1504, compared to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA).

METHODS:

A 24-week open-label trial of MTX and CH-1504 was performed in 20 patients with RA.

RESULTS:

Improvements in clinical and laboratory indicators were observed in both study groups. Improvement in the CH-1504 group was greater than in the MTX group. Both treatments were generally well tolerated; however, the liver function test abnormalities and gastrointestinal related adverse events expected with this class of medication were not seen with CH-1504.

CONCLUSION:

CH-1504 appears to be clinically efficacious and may possess a superior safety and tolerance profile compared to MTX.

PMID:
16652417
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk